Thanks to our close relationship with vendors and manufacturers, we have the unique capability to find niche products and hard to find medicines. You can rely on us for getting the newest approved products on the market and those not yet available in some countries. Our range of products is so wide, you won’t need to look for other suppliers.
with a wide clients’ base consisting of hospitals, private clinics, pharmacies and distributors, we have developed a deep knowledge of what the needs, constraints and priorities are for each of our clients. That is why we understand your urgency and we can fully meet your demands with the highest standards of service.
Our stringent operating procedures guarantee every step of handling, storage and distribution of all medicinal products.
When you contact us at Elixi, you know you are getting the best customer service: our dedicated people will offer you quick responses, personalised approach and bespoke solutions. Our approach is not to follow only standard procedures but to take care of every specific detail, of each request and individual issues.
EMA has recommended the granting of marketing authorisations for two new antiretroviral (ARV) medicines, Rekambys (rilpivirine) and Vocabria injection (cabotegravir), to be
The U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of
Jyseleca is a medicine for treating adults with moderate to severe rheumatoid arthritis, a disease in which the immune system
The Food and Drug Administration has approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic
EMA has recommended granting an extension of indication for Velphoro (sucroferric oxyhydroxide) to include control of serum phosphorus levels in children aged 2
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
